Clinical Trial Update: Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating venetoclax plus azacitidine as bridging therapy before hematopoietic stem cell transplantation in patients with higher-ri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Neoplasms

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Yehui Tan | Conditions: Myelodysplastic Neoplasms, Transplantation | Phase 2 | Status: RECRUITING